

Bhumsuk Keam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1531235/publications.pdf>

Version: 2024-02-01

251
papers

10,109
citations

53794

45
h-index

48315

88
g-index

256
all docs

256
docs citations

256
times ranked

14867
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01). <i>Cancer Research and Treatment</i> , 2022, 54, 109-117.	3.0	5
2	Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-“Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 140-149.	3.0	4
3	Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). <i>Korean Journal of Internal Medicine</i> , 2022, 37, 190-200.	1.7	2
4	Hospice-Palliative Medicine as a Model of Value-based Healthcare. <i>Journal of Korean Medical Science</i> , 2022, 37, e111.	2.5	2
5	Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer. <i>Scientific Reports</i> , 2022, 12, 2983.	3.3	0
6	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
7	Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement. <i>The Korean Journal of Hospice and Palliative Care</i> , 2022, 25, 1-11.	0.7	8
8	Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. <i>Current Problems in Cancer</i> , 2022, 46, 100848.	2.0	5
9	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60â€‰%mg Per Day Compared with the Cabozantinib Capsule at 140â€‰%mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 515-524.	4.5	9
10	The impact of COVID-19 on cancer care in a tertiary hospital in Korea: possible collateral damage to emergency care. <i>Epidemiology and Health</i> , 2022, 44, e2022044.	1.9	3
11	Comparable Clinical Outcome Using Small or Large Gross Tumor Volume-to-Clinical Target Volume Margin Expansion in Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	1.3	0
12	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14557-e14557.	1.6	0
13	Cabozantinib (C) versus placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on prior VEGFR-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40,	1.6	2
14	Cabozantinib versus placebo in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on histology subtypes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6081-6081.	1.6	1
15	A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17â€‰“11). <i>Clinical Cancer Research</i> , 2022, 28, 4240-4247.	7.0	10
16	Impact of family caregiversâ€™™ awareness of the prognosis on their quality of life/depression and those of patients with advanced cancer: a prospective cohort study. <i>Supportive Care in Cancer</i> , 2021, 29, 397-407.	2.2	10
17	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1605-1617.	4.2	8
18	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	3.3	17

#	ARTICLE	IF	CITATIONS
19	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1755-1769.	4.2	4
20	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 699-711.	2.8	12
21	Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment. <i>Cancer Research and Treatment</i> , 2021, 53, 1195-1203.	3.0	4
22	Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients. <i>Annals of Laboratory Medicine</i> , 2021, 41, 207-213.	2.5	5
23	Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma. <i>Processes</i> , 2021, 9, 792.	2.8	1
24	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. <i>Haematologica</i> , 2021, 106, 2277-2280.	3.5	9
25	Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2021, 53, 584-592.	3.0	10
26	Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4560-4560.	1.6	15
27	Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6001-6001.	1.6	5
28	Practical Considerations in Providing End-of-Life Care for Dying Patients and Their Family in the Era of COVID-19. <i>The Korean Journal of Hospice and Palliative Care</i> , 2021, 24, 130-134.	0.7	2
29	Effects of percutaneous injection laryngoplasty on voice and swallowing problems in <scp>cancer-related</scp> unilateral vocal cord paralysis. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 800-806.	1.5	2
30	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1624-1632.	2.6	0
31	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5272-5279.	7.0	26
32	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR T790M-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1859-1871.	1.1	16
33	Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors. , 2021, , .		4
34	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	3.0	14
35	Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1126-1138.	10.7	136
36	Cancer Patients'™ Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea. <i>Cancers</i> , 2021, 13, 3883.	3.7	48

#	ARTICLE	IF	CITATIONS
37	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 491-501.	11.4	192
38	Korean Version of the Patient Dignity Inventory: Translation and Validation in Patients With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 416-424.e2.	1.2	0
39	Tumor β and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 619-630.	1.9	8
40	Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. <i>Cancer Research</i> , 2021, 81, 1001-1013.	0.9	10
41	Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 175-181.	1.7	13
42	Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times. <i>Cancer Informatics</i> , 2021, 20, 117693512110516.	1.9	1
43	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. <i>Scientific Reports</i> , 2021, 11, 19712.	3.3	54
44	Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 975-984.	1.7	5
45	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
46	433...A phase 2 study of evorpcept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04. , 2021, 9, A463-A463.		0
47	439...A phase 2 study of evorpcept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03. , 2021, 9, A469-A469.		0
48	Re-irradiation for recurrent or second primary head and neck cancer. <i>Radiation Oncology Journal</i> , 2021, 39, 279-287.	1.5	7
49	Care for critically and terminally ill patients and moral distress of physicians and nurses in tertiary hospitals in South Korea: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0260343.	2.5	4
50	Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 937-944.	4.1	14
51	A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 4, as a single dose and multiple doses in patients with solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 445-456.	2.6	16
52	Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020, 71, 422-425.	5.8	32
53	Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 185-192.	1.3	15
54	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. <i>Cancer Letters</i> , 2020, 495, 135-144.	7.2	8

#	ARTICLE	IF	CITATIONS
55	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG16-07. <i>Thoracic Cancer</i> , 2020, 11, 3482-3489.	1.9	16
56	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN18-12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3359-3369.	2.5	12
57	HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2243-2250.	3.7	25
58	Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5358-5367.	7.0	53
59	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	10.7	324
60	Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). <i>BMC Cancer</i> , 2020, 20, 813.	2.6	39
61	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. <i>Theranostics</i> , 2020, 10, 10838-10848.	10.0	39
62	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. , 2020, 8, e000873.		49
63	Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre-chemotherapy tumor growth rate. <i>Chinese Clinical Oncology</i> , 2020, 9, 15-15.	1.2	9
64	Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>Journal of Infectious Diseases</i> , 2020, 222, 1902-1909.	4.0	33
65	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
66	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00613.	2.4	6
67	Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. <i>Liver Cancer</i> , 2020, 9, 182-192.	7.7	14
68	The Impacts of Prognostic Awareness on Mood and Quality of Life Among Patients With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 904-912.	1.4	18
69	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
70	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 109-109.	1.6	49
71	Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6503-6503.	1.6	15
72	A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6597-TPS6597.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients. <i>Cancer Research and Treatment</i> , 2020, 52, 917-924.	3.0	27
74	Barriers to Counseling on Advance Directives Based on Counselors's Experiences: Focus Group Interviews. <i>The Korean Journal of Hospice and Palliative Care</i> , 2020, 23, 126-138.	0.7	0
75	Squamous cell carcinoma of head and neck: what internists should know. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1031-1044.	1.7	19
76	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. <i>Annals of Translational Medicine</i> , 2020, 8, 1389.	1.7	0
77	288...A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. , 2020, , .		0
78	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1556-1566.	1.1	28
79	Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 462.	8.6	41
80	Efficacy of a Decision Aid Consisting of a Video and Booklet on Advance Care Planning for Advanced Cancer Patients: Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 940-948.e2.	1.2	12
81	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2117-2123.	1.9	9
82	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 122-128.	2.0	38
83	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 7680.	3.3	36
84	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 331-338.e4.	2.6	47
85	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. <i>Cytotherapy</i> , 2019, 21, 603-611.	0.7	15
86	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. <i>BMC Cancer</i> , 2019, 19, 196.	2.6	126
87	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 751-e231.	3.7	21
88	Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and		

#	ARTICLE	IF	CITATIONS
91	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019, 4, e000575.	4.5	5
92	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019, 19, 19.	2.6	66
93	Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases. <i>Oral Oncology</i> , 2019, 89, 84-94.	1.5	27
94	Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. <i>Investigational New Drugs</i> , 2019, 37, 579-583.	2.6	36
95	Significance of 18F-FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non-small-cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. <i>Clinical Lung Cancer</i> , 2019, 20, e9-e23.	2.6	11
96	Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. <i>Oncoimmunology</i> , 2019, 8, e1515057.	4.6	54
97	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2019, 24, 20.	3.7	29
98	Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 146-146.	1.6	7
99	Interim analysis of ibrutinib plus paclitaxel for patients with metastatic urothelial carcinoma previously treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 365-365.	1.6	1
100	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 885-893.	1.7	9
101	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1313-1323.	1.7	12
102	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1116-1124.	1.7	6
103	Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform. <i>Investigative and Clinical Urology</i> , 2019, 60, 235.	2.0	25
104	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 169-177.	3.0	3
105	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 300-312.	3.0	48
106	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. <i>Cancer Research and Treatment</i> , 2019, 51, 951-962.	3.0	48
107	TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 413-414.	3.0	7
108	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1231-1240.	3.0	20

#	ARTICLE	IF	CITATIONS
109	The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis. <i>Cancer Research and Treatment</i> , 2019, 51, 1313-1323.	3.0	34
110	Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 1549-1556.	3.0	36
111	Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 894-901.	1.7	0
112	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1083-1088.	1.3	145
113	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018, 109, 771-776.	3.9	48
114	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 736-744.	1.9	31
115	Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey. <i>Cancer Medicine</i> , 2018, 7, 1784-1793.	2.8	22
116	Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naïve prostate cancer (LATITUDE): an international, randomised phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 194-206.	10.7	126
117	Cancer Pain Management Education Rectifies Patients' Misconceptions of Cancer Pain, Reduces Pain, and Improves Quality of Life. <i>Pain Medicine</i> , 2018, 19, 2546-2555.	1.9	19
118	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 459-470.	4.2	132
119	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600E Mutant Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 7-13.	1.6	630
120	The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1186-1193.	3.0	17
121	Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Cancer Research and Treatment</i> , 2018, 50, 670-680.	3.0	9
122	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	9.4	206
123	Feasibility of an eight-week outpatient-based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea. <i>Thoracic Cancer</i> , 2018, 9, 1069-1073.	1.9	8
124	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
125	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 202.	2.2	7
126	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018, 3, e000332.	4.5	55

#	ARTICLE	IF	CITATIONS
127	Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer. <i>Medicine (United States)</i> , 2018, 97, e10778.	1.0	12
128	A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4510-4510.	1.6	8
129	A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8575-8575.	1.6	7
130	MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9105-TPS9105.	1.6	6
131	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. <i>PLoS ONE</i> , 2018, 13, e0189766.	2.5	46
132	Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives. <i>Cancer Research and Treatment</i> , 2018, 50, 614-623.	3.0	23
133	The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 720-728.	3.0	14
134	Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18015-e18015.	1.6	0
135	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). <i>Cancer</i> , 2017, 123, 1958-1964.	4.1	44
136	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. <i>European Journal of Cancer</i> , 2017, 75, 141-149.	2.8	84
137	MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. <i>Lung Cancer</i> , 2017, 106, 131-137.	2.0	30
138	P3.02c-061 Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti-PD-1 Antibody in Patients with Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1312-S1313.	1.1	1
139	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>American Journal of Pathology</i> , 2017, 187, 980-986.	3.8	44
140	Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. <i>Clinical Lung Cancer</i> , 2017, 18, e169-e178.	2.6	20
141	Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. <i>Cancer</i> , 2017, 123, 841-848.	4.1	32
142	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	12.8	115
143	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 520-528.	1.1	21
144	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017, 49, 1033-1043.	3.0	19

#	ARTICLE	IF	CITATIONS
145	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 3065-3074.	1.6	349
146	Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6009-6009.	1.6	41
147	Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600E mutated anaplastic thyroid cancer (ATC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6023-6023.	1.6	16
148	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	1.8	69
149	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 514-522.	1.7	21
150	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 416-422.	3.0	27
151	Prognostic implications of <i>FGFR1</i> and <i>MYC</i> status in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 9803.	3.3	11
152	The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 907-916.	3.0	44
153	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 570-578.	1.7	38
154	Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1074.	4.1	26
155	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016, 16, 425-433.	1.7	18
156	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Clinical Lung Cancer</i> , 2016, 17, 245-252.e1.	2.6	20
157	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 α and STAT3. <i>Oncolmmunology</i> , 2016, 5, e1108514.	4.6	124
158	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	1.6	715
159	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515.	2.6	11
160	Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1217-1218.	2.4	2
161	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016, 38, 277-284.	2.0	14
162	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 116.	2.6	31

#	ARTICLE	IF	CITATIONS
163	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. <i>Cancer Research and Treatment</i> , 2016, 48, 304-311.	3.0	9
164	Phase I Study of Random Healthy Donorâ€Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 215-224.	3.4	128
165	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 707-714.	2.5	8
166	Factors Related to the Differential Preference for Cardiopulmonary Resuscitation Between Patients With Terminal Cancer and That of Their Respective Family Caregivers. <i>American Journal of Hospice and Palliative Medicine</i> , 2016, 33, 20-26.	1.4	12
167	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Nonâ€Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 263-270.e2.	2.6	107
168	Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Nonâ€Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1387-1396.	4.1	25
169	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016, 22, 2261-2270.	7.0	217
170	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. <i>BMC Cancer</i> , 2016, 16, 170.	2.6	30
171	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 873-883.	2.5	17
172	Efficacy of BCG398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with <i>FGFR3</i> alterations.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4517-4517.	1.6	19
173	Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6010-6010.	1.6	25
174	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6012-6012.	1.6	33
175	Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6017-6017.	1.6	7
176	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6090-6090.	1.6	3
177	Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6091-6091.	1.6	38
178	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013.	1.6	16
179	An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS6102-TPS6102.	1.6	3
180	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 15901-15914.	1.8	125

#	ARTICLE	IF	CITATIONS
181	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8389.	3.3	22
182	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1140-1149.	1.7	26
183	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 88-97.	3.0	19
184	Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. <i>Journal of Clinical Oncology</i> , 2016, 34, 6078-6078.	1.6	0
185	Korean Cancer Patients's Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10067-10067.	1.6	0
186	Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. <i>Blood</i> , 2016, 128, 4222-4222.	1.4	0
187	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2016, , .	1.7	0
188	Quality of life changes and intensive care preferences in terminal cancer patients. <i>Palliative and Supportive Care</i> , 2015, 13, 1309-1316.	1.0	13
189	Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1189-1194.	1.1	26
190	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. <i>Cancer</i> , 2015, 121, 2612-2617.	4.1	63
191	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 555-563.	3.0	49
192	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0133371.	2.5	7
193	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 194, 1112-1119.	0.4	19
194	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2015, 90, 381-387.	2.0	44
195	Mechanisms of Acquired Resistance to AZD9291. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1736-1744.	1.1	202
196	Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2015, 56, 2032-2038.	1.3	43
197	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2379-2387.	7.0	116
198	Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). <i>Annals of Hematology</i> , 2015, 94, 437-444.	1.8	32

#	ARTICLE	IF	CITATIONS
199	Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. <i>Modern Pathology</i> , 2015, 28, 1154-1166.	5.5	143
200	Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1073-1081.	2.5	6
201	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. <i>Oncologist</i> , 2015, 20, 1119-1120.	3.7	20
202	A Possible Association Between Thyroid Cancer and Breast Cancer. <i>Thyroid</i> , 2015, 25, 1330-1338.	4.5	57
203	Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3486-3493.	3.6	19
204	<i>ABCB1</i> polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. <i>Cancer Science</i> , 2015, 106, 86-93.	3.9	59
205	An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients. <i>International Journal of Cancer</i> , 2015, 136, 162-171.	5.1	38
206	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 44971-44984.	1.8	13
207	Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy. <i>Radiation Oncology Journal</i> , 2015, 33, 98.	1.5	22
208	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 891-898.	1.7	10
209	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 182-188.	3.0	3
210	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. <i>Cancer Research and Treatment</i> , 2015, 47, 630-637.	3.0	21
211	Effects of the education program for patients with cancer pain.. <i>Journal of Clinical Oncology</i> , 2015, 33, 193-193.	1.6	0
212	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. <i>Anticancer Research</i> , 2015, 35, 175-82.	1.1	29
213	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. <i>Lung Cancer</i> , 2014, 86, 363-368.	2.0	17
214	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1430.	7.4	136
215	Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, e1-e6.	2.6	1
216	Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. <i>Breast Cancer</i> , 2014, 21, 387-393.	2.9	14

#	ARTICLE	IF	CITATIONS
217	Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 594-600.	2.2	92
218	The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 2135-2142.	2.5	18
219	The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: A retrospective cohort study. <i>Lung Cancer</i> , 2014, 85, 320-325.	2.0	6
220	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2014, 46, 323-330.	3.0	21
221	Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review. <i>Cancer Research and Treatment</i> , 2014, 46, 93-97.	3.0	32
222	Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9543-9543.	1.6	0
223	Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17032-e17032.	1.6	0
224	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. <i>Supportive Care in Cancer</i> , 2013, 21, 1437-1444.	2.2	48
225	Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. <i>Breast Cancer</i> , 2013, 20, 167-173.	2.9	17
226	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013, 119, 1195-1202.	4.1	136
227	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2242-2249.	1.5	12
228	Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. <i>Supportive Care in Cancer</i> , 2013, 21, 183-190.	2.2	38
229	Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. <i>Clinical Lung Cancer</i> , 2013, 14, 383-389.	2.6	63
230	Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 116, 55-60.	0.4	7
231	Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1069-1074.	1.1	110
232	Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 415-422.	1.1	147
233	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. , 2013, 21, 1437.		1
234	A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6069-6069.	1.6	4

#	ARTICLE	IF	CITATIONS
235	Solitary Splenic Metastasis from Head and Neck Cancer: A Case Report. Korean Journal of Medicine, 2013, 85, 324.	0.3	1
236	How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution. Cancer Research and Treatment, 2013, 45, 178-185.	3.0	11
237	Predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision cross-complementing-1 (ERCC1) in advanced urothelial carcinoma (UC) treated with first-line gemcitabine (G) and platinum (P)-based chemotherapy (CT).. Journal of Clinical Oncology, 2013, 31, e15614-e15614.	1.6	0
238	Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, e18555-e18555.	1.6	0
239	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. Journal of Neuro-Oncology, 2012, 106, 303-313.	2.9	64
240	Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7566-7566.	1.6	1
241	Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. Journal of Clinical Oncology, 2012, 30, 5552-5552.	1.6	0
242	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Research, 2011, 13, R22.	5.0	187
243	Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 465-477.	4.9	24
244	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1301-1308.	2.5	32
245	Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer, 2011, 11, 452.	2.6	61
246	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2009, 116, 153-160.	2.5	41
247	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer, 2008, 8, 148.	2.6	64
248	Aggressiveness of Cancer-Care near the End-of-Life in Korea. Japanese Journal of Clinical Oncology, 2008, 38, 381-386.	1.3	94
249	A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α -fetoprotein as a predictive and prognostic marker. Molecular Medicine Reports, 2008, 1, 415-22.	2.4	8
250	Pneumatosis Intestinalis with Pneumoperitoneum Mimicking Intestinal Perforation in a Patient with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Korean Journal of Internal Medicine, 2007, 22, 40.	1.7	12
251	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer, 2007, 7, 203.	2.6	126